Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2003 Mar 29;326(7391):689.
doi: 10.1136/bmj.326.7391.689.

Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices

Julia Hippisley-Cox  1 , Ruth Cater, Mike Pringle, Carol Coupland
Affiliations
Multicenter Study

Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices

Julia Hippisley-Cox et al. BMJ. .

Abstract

Objective: To compare the effectiveness of lipid lowering drugs in lowering serum cholesterol concentrations.

Design: Cross sectional study.

Setting: 17 practices within 17 primary care groups in Trent region, United Kingdom.

Participants: Patients aged 35 years or over taking lipid lowering drugs and with at least two serum cholesterol concentrations recorded on computer.

Main outcome measures: Proportion of patients achieving serum cholesterol concentration of < or =5 mmol/l and mean percentage reduction in serum cholesterol concentration.

Results: 1353 of 2469 (54.8%) patients receiving lipid lowering treatment had a last recorded serum cholesterol concentration of < or =5 mmol/l. Significantly more patients taking statins achieved the target value for serum cholesterol (5 mmol/l) than those taking fibrates (1307 (57%) v 46 (26%); P<0.0001). Atorvastatin and simvastatin were the most effective drugs in achieving the target. Significant differences were found between lipid lowering drugs for the pretreatment serum cholesterol concentration, the most recent cholesterol concentration, and the associated percentage reduction. Atorvastatin and simvastatin achieved the greatest percentage reduction in serum cholesterol concentrations (30.1%, 95% confidence interval 28.8% to 31.4%, and 28.0%, 26.7% to 29.3%, respectively). Although the mean serum cholesterol concentrations in this unselected population tended to be higher than those in clinical trials, the percentage reduction was consistent with the trials.

Conclusion: The ability of individual statins to lower serum cholesterol concentration varied, with atorvastatin and simvastatin being the most effective. The percentage reductions agreed with those of randomised controlled trials indicating likely benefits in unselected patients in primary care. As the initial serum cholesterol concentrations were higher than those in randomised controlled trials, target serum cholesterol values of < or =5 mmol/l may be unrealistic even for patients taking the most efficacious drugs. Also, the higher initial levels could mean that the absolute reduction in cardiovascular risk in primary care patients is greater than thought.

PubMed Disclaimer

Figures

Figure
Figure
Flow of patients through study
See this image and copyright information in PMC

Comment in

References

    1. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. - PubMed
    1. Long-term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357. - PubMed
    1. Sacks FM, Pfeffer MA, Moye LA. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The CARE study. N Engl J Med. 1996;335:1001–1009. - PubMed
    1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. - PubMed
    1. Department of Health. National service framework for coronary artery disease: modern standards and service models. London: Stationery Office; 2000.

Publication types

Substances